Trial intelligence / Profile preview

Tarceva maintenance in advanced NSCLC (IUNO)

NCT01328951Phase 3Completed

Sponsor
Roche
Start
Sep 2011
Primary completion
Dec 2015
Modality
Small Molecules
Countries
20
01

Overview

A Phase 3 trial of erlotinib in non-small cell lung cancer (NSCLC), sponsored by Roche. Started Sep 2011; status: completed.

02

Drugs

erlotinib
03

Conditions

non-small cell lung cancer (NSCLC)

Beyond the preview

Go deeper on NCT01328951.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT01328951.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call